Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XKH002 in Advanced or Metastatic Solid Tumors
NCT06196762Phase 1Recruiting
- Sponsor
- Kanova
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of XKH-002 in solid tumor (advanced stage) and metastatic solid tumor, sponsored by Kanova. Primary endpoints: Maximum Tolerated Dose, Maximum Administered Dose, and Recommended Dose for Expansion at 24 months and Safety and Tolerability at 24 months. Started Nov 2023; status: recruiting.
02
Drugs
XKH-002
03
Conditions
solid tumor (advanced stage)metastatic solid tumor
Beyond the preview
Go deeper on NCT06196762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06196762.